Halo Collective Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Halo Collective's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 23% per year.
Belangrijke informatie
-48.7%
Groei van de winst
61.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 23.0% |
| Rendement op eigen vermogen | -126.4% |
| Nettomarge | -333.9% |
| Laatste winstupdate | 30 Sep 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Halo Collective geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 22 | 28 | -95 | 38 | 0 |
| 30 Jun 22 | 32 | -99 | 43 | 0 |
| 31 Mar 22 | 34 | -99 | 44 | 0 |
| 31 Dec 21 | 36 | -95 | 42 | 0 |
| 30 Sep 21 | 33 | -54 | 39 | 0 |
| 30 Jun 21 | 31 | -47 | 31 | 0 |
| 31 Mar 21 | 27 | -42 | 25 | 0 |
| 31 Dec 20 | 22 | -41 | 22 | 0 |
| 30 Sep 20 | 19 | -33 | 24 | 0 |
| 30 Jun 20 | 20 | -35 | 27 | 0 |
| 31 Mar 20 | 24 | -33 | 26 | 0 |
| 31 Dec 19 | 28 | -28 | 24 | 0 |
| 30 Sep 19 | 28 | -17 | 17 | 0 |
| 30 Jun 19 | 25 | -17 | 14 | 0 |
| 31 Mar 19 | 17 | -15 | 11 | 0 |
| 31 Dec 18 | 11 | -14 | 9 | 0 |
| 30 Sep 18 | 10 | -15 | 11 | 0 |
| 30 Jun 18 | 10 | -11 | 10 | 0 |
| 31 Mar 18 | 10 | -10 | 10 | 0 |
| 31 Dec 17 | 10 | -9 | 9 | 0 |
| 31 Dec 16 | 5 | 0 | 1 | 0 |
Kwaliteitswinsten: A9KN is currently unprofitable.
Groeiende winstmarge: A9KN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: A9KN is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Versnelling van de groei: Unable to compare A9KN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: A9KN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Rendement op eigen vermogen
Hoge ROE: A9KN has a negative Return on Equity (-126.35%), as it is currently unprofitable.